Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNAQNASDAQ:GNCANASDAQ:PHASNASDAQ:PLXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAQAllena Pharmaceuticals$0.00+∞$0.00$0.00▼$0.02N/AN/AN/A96,558 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAQAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%+150.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+6,910.00%PLXPPLx Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAQAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAQAllena Pharmaceuticals 0.00N/AN/AN/AGNCAGenocea Biosciences 0.00N/AN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/APLXPPLx Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAQAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AGNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAQAllena PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AGNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAQAllena PharmaceuticalsN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAQAllena PharmaceuticalsN/AN/AN/AGNCAGenocea Biosciences0.241.351.35PHASPhaseBio PharmaceuticalsN/A0.470.47PLXPPLx PharmaN/A4.794.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAQAllena PharmaceuticalsN/AGNCAGenocea Biosciences0.64%PHASPhaseBio Pharmaceuticals49.02%PLXPPLx Pharma21.19%Insider OwnershipCompanyInsider OwnershipALNAQAllena Pharmaceuticals3.70%GNCAGenocea Biosciences1.61%PHASPhaseBio Pharmaceuticals9.90%PLXPPLx Pharma8.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNAQAllena Pharmaceuticals12N/AN/ANot OptionableGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionableGNCA, ALNAQ, PHAS, and PLXP HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Protalix (PLX)February 3, 2025 | markets.businessinsider.comGRAVITY Co (NASDAQ:GRVY) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comPLXp/USD - Pullix US DollarAugust 25, 2024 | investing.comProtalix Biotherapeutics Inc (PLX)January 30, 2024 | investing.comVertex Pharmaceuticals Inc VRTXJanuary 22, 2024 | morningstar.comVietnam National Petroleum Group (PLX)October 23, 2023 | investing.comPLx Pharma Inc (PLXPQ)August 21, 2023 | uk.investing.comPharmaceutical R&D: the road to positive returnsJuly 16, 2023 | nature.comPLXPQ PLx Pharma Inc.April 21, 2023 | seekingalpha.comPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its AssetsApril 13, 2023 | marketwatch.comWhy PLx Pharma Shares Are Nosediving TodayApril 12, 2023 | msn.comWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketApril 12, 2023 | msn.comWhy PLx Pharma Shares Are Down Over 40% TuesdayApril 11, 2023 | msn.comPLx Pharma Inc. Receives Nasdaq Delisting NoticeApril 11, 2023 | finance.yahoo.comShort Volatility Alert: Plx Pharma IncApril 11, 2023 | msn.comPLx Pharma's Return On Capital Employed InsightsDecember 22, 2022 | msn.comPLx Pharma (PLXP) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | seekingalpha.comPLx Pharma down after Q3 revenue fell 94% Y/YNovember 11, 2022 | seekingalpha.comPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.comPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryLululemon, UNH, Enphase: Bad News, Good Opportunity?By Thomas Hughes | June 17, 2025View Lululemon, UNH, Enphase: Bad News, Good Opportunity?Uber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo PartnershipGNCA, ALNAQ, PHAS, and PLXP Company DescriptionsAllena Pharmaceuticals NASDAQ:ALNAQAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 18, 2023.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.PLx Pharma NASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
